Novartis AG (NOVN)
NOVN · Health Care · 
Switzerland
Novartis AG (NOVN) is a Swiss company in the Health Care sector. The stock has its largest weight in SPFS (MSCI World Health Care), at 3.23%. Anyone who holds an ETF containing Novartis also has an indirect stake in the company.
Data and Charts: Novartis
Key Data for Novartis
Alysly Data Analysis: Novartis
Novartis Connections
The map shows how Novartis connects to ETFs, indices and other names. Each link is based on measured data and is not a recommendation.
- MSCI Europe Index · contains
- MSCI World ex USA Index · contains
- MSCI World Health Care Index · contains
- MSCI World Minimum Volatility Index · contains
- STOXX Europe 600 Index · contains
- EXSA ETF · holds
- X600 ETF · holds
- XESU ETF · holds
- EXUS ETF · holds
- EXU1 ETF · holds
- IMEA ETF · holds
- SPYE ETF · holds
- XDEB ETF · holds
- XDWH ETF · holds
- SPFS ETF · holds
- XMEU ETF · holds
- XSX6 ETF · holds
- XIEE ETF · holds
- XSX7 ETF · holds
- Galderma Group N Stock · similar ETF exposure
- Straumann Holding Stock · similar ETF exposure
What ETF Is Novartis In?
Novartis has very high ETF coverage and is held by 28 of the 104 ETFs we track, which together follow 13 indices. That puts the stock in more ETFs than 96.9% of the 4,341 stocks we track.
| ETF | Index | Weight | per €1,000 in the ETF |
|---|---|---|---|
| SPFS | MSCI World Health Care | 3.23% | €32.34 |
| XDWH | MSCI World Health Care | 3.23% | €32.31 |
| SPYE | MSCI Europe | 2.13% | €21.32 |
| XMEU / XIEE | MSCI Europe | 2.13% | €21.26 |
| IMEA | MSCI Europe | 2.12% | €21.20 |
| X600 / XESU | STOXX Europe 600 | 2.02% | €20.15 |
| EXSA | STOXX Europe 600 | 2.01% | €20.10 |
| XSX6 / XSX7 | STOXX Europe 600 | 2.01% | €20.08 |
| 2B7K | MSCI World SRI | 1.34% | €13.40 |
| EXUS / EXU1 | MSCI World ex USA | 1.19% | €11.93 |
| XDEB | MSCI World Minimum Volatility | 1.19% | €11.87 |
| XDEM | MSCI World Momentum | 0.96% | €9.63 |
| WVAL | MSCI World Value | 0.83% | €8.27 |
| XDEQ | MSCI World Quality | 0.61% | €6.12 |
| SWWD | MSCI World | 0.33% | €3.30 |
| SPPW | MSCI World | 0.33% | €3.30 |
| XDWD / XDWL | MSCI World | 0.32% | €3.21 |
| EUNL | MSCI World | 0.32% | €3.20 |
| WIMI | MSCI World IMI | 0.29% | €2.87 |
| SPYY | MSCI ACWI | 0.29% | €2.87 |
| IUSQ | MSCI ACWI | 0.28% | €2.80 |
| SPYI / SPSA | MSCI ACWI IMI | 0.25% | €2.53 |
The last column shows how much of €1,000 in one of these funds goes to Novartis, based on each fund's latest holdings list.
US-listed ETFs holding Novartis (weight per latest SEC filing): VXUS 0.66%. These funds are registered in the US; retail investors in the EU usually cannot buy them.
Novartis Weight in iShares Core MSCI World (EUNL) Since 2019
In iShares Core MSCI World (EUNL), Novartis had a weight of 0.45% on Sep 30, 2019 and 0.32% on Oct 29, 2026. The fund tracks the MSCI World. Its share peaked at 0.51% on Mar 31, 2020. The weight rises and falls with the stock's price performance relative to the other index members. It can also change when the index provider adjusts the index composition.
What's Inside Your ETF Portfolio and the ETF overlap check show how much Novartis overlaps with the rest of a portfolio.
Stocks With ETF Exposure Similar to Novartis
| Stock | Shared ETFs | r |
|---|---|---|
| Novartis | – | – |
 Galderma Group N | 25 | – |
| Straumann Holding | 25 | – |
| Novo Nordisk A/S | 25 | – |
 Glaxosmithkline | 25 | – |
| Alcon | 24 | – |
 Lonza Group | 24 | – |
| Sonova Holding | 24 | – |
| Coloplast A/S | 24 | – |
These stocks reach a portfolio through largely the same funds as Novartis. “Shared ETFs” counts the funds that hold both.
Fundamental Analysis: Novartis
Latest Patents Granted to Novartis
In the 52 weekly issues of the US patent office from Nov 4, 2025 to Oct 27, 2026, Novartis received 69 utility patents. That is 0.022% of all utility patents the US patent office granted in those weeks. The median time from filing to grant was 4.6 years.
| Granted | Patent | Title | Filed | Technology field |
|---|---|---|---|---|
| US 12774275 B2 | Compounds and compositions for the treatment of coronaviral related diseases | C07D Chemistry; metallurgy | ||
| US 12767731 B2 | Anti-IgE antibody therapy for multiple food allergies | C07K Chemistry; metallurgy | ||
| US 12767723 B2 | Treatment for lupus nephritis using anti-BAFFR antibodies | C07K Chemistry; metallurgy | ||
| US 12767647 B2 | Glue degraders and methods of use thereof | C07D Chemistry; metallurgy | ||
| US 12760031 B2 | Pyridine-3-carboxylate compounds as CAV1.2 activators | C07D Chemistry; metallurgy |
These are grants, not applications. The office usually publishes an application 18 months after the priority date; the grant tends to come much later. Owners counted: NOVARTIS AG. Titles as published by the office; median time based on 34 patents with a known filing date.
The patent screener lists more grants, filterable by company, type and technology field. The M&A and patents page compares companies.
